

## **Table of Contents**

**State/Territory Name: DC**

**State Plan Amendment (SPA) #: 23-0012**

This file contains the following documents in the order listed:

- 1) Approval Letter
- 2) CMS 179 Form/Summary Form (with 179-like data)
- 3) Approved SPA Pages

**DEPARTMENT OF HEALTH & HUMAN SERVICES**

Centers for Medicare & Medicaid Services  
Center for Medicaid & CHIP Services  
233 North Michigan Ave., Suite 600  
Chicago, Illinois 60601



---

**Financial Management Group**

October 27, 2023

Melisa Byrd  
Senior Deputy Director/Medicaid Director  
441 4<sup>th</sup> Street, NW, 9<sup>th</sup> Floor, South  
Washington, DC 20001

RE: TN 23-0012

Dear Byrd:

We have reviewed the proposed D.C. State Plan Amendment (SPA) to Attachment 4.19-B which was received by the Centers for Medicare & Medicaid Services (CMS) on September 15, 2023. This plan amendment will update payment for physician-administered drugs. It will also allow the Department of Health Care Finance to reimburse the entire class of physician-administered drugs at one hundred percent (100%) of Medicare rates.

Based upon the information provided by the State, we have approved the amendment with an effective date of October 1, 2023. We are enclosing the approved CMS-179 and the state plan pages.

If you have any additional questions or need further assistance, please contact Lindsay Michael at 410-786-7197 or [Lindsay.michael@cms.hhs.gov](mailto:Lindsay.michael@cms.hhs.gov)

Sincerely,



Todd McMillion  
Director  
Division of Reimbursement Review

Enclosures

<b>TRANSMITTAL AND NOTICE OF APPROVAL OF STATE PLAN MATERIAL</b> <b>FOR: CENTERS FOR MEDICARE &amp; MEDICAID SERVICES</b>	1. TRANSMITTAL NUMBER: <b>DC 23-0012</b>	2. STATE: <b>District of Columbia</b>
	3. PROGRAM IDENTIFICATION: TITLE <u>XIX</u> OF THE SOCIAL SECURITY ACT	
TO: CENTER DIRECTOR CENTERS FOR MEDICARE & MEDICAID SERVICES DEPARTMENT OF HEALTH AND HUMAN SERVICES	4. PROPOSED EFFECTIVE DATE: <b>October 1, 2023</b>	
5. FEDERAL STATUTE/REGULATION CITATION: <b>42 CFR § 447.201</b>	6. FEDERAL BUDGET IMPACT (Amounts in WHOLE dollars): a. FFY <u>2024</u> <u>\$257,860</u> b. FFY <u>2025</u> <u>\$282,715</u>	
7. PAGE NUMBER OF THE PLAN SECTION OR ATTACHMENT: <b>Attachment 4.19-B Page 3c</b>	8. PAGE NUMBER OF THE SUPERSEDED PLAN SECTION OR ATTACHMENT (If Applicable): <b>Page 4.19-B Page 3c</b>	

9. SUBJECT OF AMENDMENT:


**Reimbursement Rates of Physician Administered Drugs**

10. GOVERNOR'S REVIEW (Check One)

- GOVERNOR'S OFFICE REPORTED NO COMMENT  
 COMMENTS OF GOVERNOR'S OFFICE ENCLOSED  
 NO REPLY RECEIVED WITHIN 45 DAYS OF SUBMITTAL

OTHER, AS SPECIFIED:  
**D.C. Act: 22-434**

11. SIGNATURE OF STATE AGENCY OFFICIAL



12. TYPED NAME

**Melisa Byrd**

13. TITLE

**Interim Director**

14. DATE SUBMITTED

09/15/2023

15. RETURN TO

Melisa Byrd  
Interim Director  
Department of Health Care Finance  
441 4<sup>th</sup> Street, NW, 9<sup>th</sup> Floor, South  
Washington, DC 20001

**FOR CMS USE ONLY**


16. DATE RECEIVED  
9/15/23

17. DATE APPROVED  
October 27, 2023

**PLAN APPROVED – ONE COPY ATTACHED**

18. EFFECTIVE DATE OF APPROVED MATERIAL  
10/1/23

19. SIGNATURE OF APPROVING OFFICIAL



20. TYPED NAME OF APPROVING OFFICIAL  
Todd McMillion

21. TITLE OF APPROVING OFFICIAL  
DRR, Director

22. REMARKS

- i. Effective October 1, 2023, physician-administered drugs shall be reimbursed at one hundred percent (100%) of the Medicare fee schedule rates. Rates will be updated annually pursuant to the Medicare fee schedule, and will be published on DHCF's website at <https://www.dc-medicaid.com/>.
- j. For physician administered drugs purchased through the Federal Public Health Service's 340B Drug Pricing Program, reimbursement shall be the 340B actual acquisition cost, but no more than the 340B ceiling price.
- k. Investigational drugs shall not be Medicaid-reimbursable.

## DEFINITIONS

For the purposes of Section 3 in this State Plan Amendment, the following terms and phrases shall have the meanings ascribed:

**Brand** – any registered trade name commonly used to identify a drug.

**Container** – A light resistant receptacle designed to hold a specific dosage form which is or maybe in direct contact with the item and does not interact physically or chemically with the item or adversely affect the strength, quality, or purity of the item.

**Department of Health Care Finance (DHCF)** – The executive department responsible for administering the Medicaid program within the District of Columbia.

**Federal Supply Schedule** – a multiple award, multi-year federal contract for medical equipment, supplies, pharmaceutical, or service programs that is available for use by federal government agencies that complies with all federal contract laws and regulations. Pricing is negotiated based on how vendors do business with their commercial customers.